• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Parkinson’s disease - Articles and news items


Prexton successfully completes phase 1 Parkinson’s disease trial

Industry news / 20 September 2016 / Niamh Louise Marriott, Digital Content Producer

This study was the first in man Phase 1 clinical trial for an mGluR4 positive allosteric modulator. The randomised, double-blind, placebo controlled single and multiple ascending dose studies were designed to assess safety and tolerability of PXT002331 dosed orally…

biomarker parkinsons brain imaging

Biomarker breakthrough could improve Parkinson’s treatment

Industry news / 16 August 2016 / University of Florida

Scientists have found that using magnetic resonance imaging reveals areas where Parkinson’s disease causes progressive decline in brain activity, a biomarker discovery which will help to evaluate new experimental treatments to slow or stop the disease’s progression…


Collaboration to explore nilotinib as a potential treatment for Parkinson’s

Industry news / 13 July 2016 / Victoria White, Digital Content Producer

Preclinical studies have shown that cancer drug nilotinib may protect neuronal cells from Parkinson’s pathology by inhibiting the activity of c-Abl…


Parkinson’s disease therapy safinamide launches in the UK

Industry news / 23 May 2016 / Victoria White, Digital Content Producer

Commenting on the launch, Maurizio Castorina, CEO of Zambon, said safinamide offers PD patients “a novel therapeutic option”…


FDA approves Nuplazid to treat hallucinations in Parkinson’s disease

Industry news / 3 May 2016 / Victoria White, Digital Content Producer

The FDA has approved Acadia’s Nuplazid, the first drug approved to treat hallucinations and delusions experienced by some people with Parkinson’s disease…

Parkinson's disease market

Parkinson’s disease market to hit $3.2 billion by 2021

Industry news / 25 February 2016 / Victoria White

GBI Research states that Parkinson’s disease market growth will occur despite the patent expiries of several key products during the forecast period…


Acorda to acquire Biotie; gains rights to tozadenant

Industry news / 19 January 2016 / Victoria White

In acquiring Biotie for approximately $363 million, Acorda will obtain worldwide rights to tozadenant, an oral adenosine A2a receptor antagonist currently in Phase 3 development in Parkinson’s disease…


Parkinson’s disease treatment pipeline holds significant potential, says GBI Research

Industry news / 12 January 2016 / Victoria White

An analyst at GBI Research states that the pipeline for the disease is highly active, consisting of 365 programmes across all stages of development, and a diverse range of molecular targets…


Nilotinib improved cognition and motor skills in Parkinson’s trial

Industry news / 19 October 2015 / Victoria White

Nilotinib, a treatment for leukaemia, improved cognition, motor skills and non-motor function in patients with Parkinson’s disease in a Phase I clinical trial…


Biotie announces start of tozadenant Phase 3 study in Parkinson’s disease

Industry news / 21 July 2015 / Victoria White

A Phase 3 study of tozadenant in patients with Parkinson’s disease experiencing levodopa related end-of-dose “wearing-off” has started…


Recent drug approvals will boost Parkinson’s disease therapeutics market

Industry news / 2 July 2015 / Victoria White

The Parkinson’s disease treatment market value across eight major countries will reach $4.7 billion by 2022, says GlobalData…


NTCELL Phase I/IIa study meets endpoints

Industry news / 15 June 2015 / Victoria White

A Phase I/IIa study of NTCELL, an regenerative cell therapy being studied as a disease-modifying agent in Parkinson’s disease, has met its endpoints…


Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +